Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial

BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with a high risk of metastasis. In 2017, avelumab (anti–programmed death-ligand 1 (PD-L1)) became the first approved treatment for patients with metastatic MCC (mMCC), based on the occurrence of durable responses in...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Immunother Cancer
Hlavní autoři: D'Angelo, Sandra P, Bhatia, Shailender, Brohl, Andrew S, Hamid, Omid, Mehnert, Janice M, Terheyden, Patrick, Shih, Kent C, Brownell, Isaac, Lebbé, Celeste, Lewis, Karl D, Linette, Gerald P, Milella, Michele, Georges, Sara, Shah, Parantu, Ellers-Lenz, Barbara, Bajars, Marcis, Güzel, Gülseren, Nghiem, Paul T
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2020
Témata:
Clinical/Translational Cancer Immunotherapy
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7239697/
https://ncbi.nlm.nih.gov/pubmed/32414862
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000674
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky